ALK rs1057519783: Understanding the G1202R Resistance Mutation
The rs1057519783 variant, commonly known as ALK G1202R, is a specific genetic change in the ALK gene that results in a glycine to arginine substitution. This mutation is primarily recognized in clinical oncology for its role in conferring resistance to various ALK-targeted tyrosine kinase inhibitor therapies in patients with non-small cell lung cancer.
What each genotype means
Typical ALK gene sequence
This genotype represents the common, wild-type sequence for this position in the ALK gene. It does not contain the specific G1202R mutation associated with acquired resistance to certain ALK-targeted therapies in lung cancer.
This is the most common genotype found in the general population.
Heterozygous G1202R mutation
This genotype indicates the presence of the G1202R mutation, which results in a glycine to arginine substitution at position 1202. In the context of ALK-positive non-small cell lung cancer, this mutation is a known mechanism of acquired resistance to several ALK-targeted therapies, including crizotinib, ceritinib, and alectinib. Patients with this finding should discuss treatment options and potential therapeutic resistance with their oncologist.
This specific mutation is extremely rare in the general population and is typically identified as an acquired somatic mutation in tumor samples.
Homozygous G1202R mutation
This genotype indicates that both copies of the ALK gene carry the G1202R mutation. Similar to the heterozygous state, this mutation is associated with significant resistance to multiple generations of ALK-targeted tyrosine kinase inhibitors. Clinical management for individuals with this mutation requires specialized oncology consultation to evaluate appropriate therapeutic strategies.
This genotype is extremely rare and is generally only observed as an acquired somatic event in specific clinical cancer contexts.
What is the rs1057519783 Variant?
The rs1057519783 variant is a missense mutation located within the ALK (Anaplastic Lymphoma Kinase) gene. In genetic terms, this variant represents a single nucleotide change where a guanine is replaced by an adenine, leading to a protein-level change where the amino acid glycine at position 1202 is replaced by arginine. This specific location is situated at the solvent front of the ALK kinase domain. Because this domain is critical for the protein's function, changes here can significantly alter how the protein interacts with therapeutic drugs. This variant is not typically inherited in the germline but is often identified as an acquired secondary mutation in tumor tissue. It is frequently detected through next-generation sequencing of circulating tumor DNA or biopsy samples in patients who have previously undergone treatment with ALK-targeted therapies.
The Role of the ALK Gene
The ALK gene provides instructions for making a protein called anaplastic lymphoma kinase, which is a receptor tyrosine kinase. In healthy individuals, this protein is primarily active during the development of the nervous system. However, in certain cancers, such as non-small cell lung cancer (NSCLC), the ALK gene can become rearranged or fused with other genes, such as EML4. These fusion proteins are constantly active, sending continuous signals to cells to grow and divide uncontrollably. Targeted therapies, known as ALK inhibitors, are designed to block this signaling pathway. When the ALK protein undergoes a structural change like the G1202R mutation, the shape of the kinase domain is altered. This structural shift can prevent the inhibitor drugs from binding effectively to the protein, allowing the cancer cells to continue their growth despite the presence of the medication.
Clinical Significance and Research Evidence
Research has consistently identified the G1202R mutation as a significant mechanism of acquired resistance to first- and second-generation ALK inhibitors, including crizotinib, alectinib, and brigatinib. The evidence for this association is considered strong within the context of clinical oncology. Studies have shown that patients who develop this mutation often experience disease progression while on these therapies. While the mutation is a well-documented hurdle in treatment, it is important to note that clinical responses can vary based on the specific inhibitor used and the patient's overall genetic profile. Some third-generation inhibitors have been developed to address resistance, though the efficacy of these drugs can still be influenced by the presence of specific mutations. Because this is a complex area of cancer research, patients should always discuss their specific molecular test results and treatment options with their oncologist.
Population Frequency and Prevalence
The rs1057519783 variant is classified as extremely rare in the general population. It is not a common inherited trait found in the general public; rather, it is a somatic mutation that arises within tumor cells during the course of cancer progression. Because it is an acquired event, its frequency is measured within specific cohorts of patients who have already been diagnosed with ALK-positive non-small cell lung cancer and have been treated with ALK inhibitors. Among this specific clinical population, the prevalence of the G1202R mutation can be significant, particularly in patients who have progressed on earlier lines of therapy. It is not a variant that individuals would typically screen for in a standard wellness or ancestry genetic test, as its clinical relevance is strictly confined to the management of specific ALK-driven malignancies.
What This Information Means for You
If you or a loved one has been identified as having the ALK G1202R mutation, it is essential to understand that this is a clinical finding related to tumor biology, not a general health risk. This information is used by medical professionals to guide the selection of targeted therapies. You cannot change this genetic variant through lifestyle, diet, or supplements. The presence of this mutation is a technical detail that helps your oncology team understand why a previous treatment may have stopped working and which alternative therapies might be more effective. Always rely on your healthcare provider to interpret these results in the context of your overall treatment plan. Do not make any changes to your medication or treatment schedule without consulting your clinician or pharmacist, as they are the only ones who can provide guidance tailored to your specific medical history.
How common is this variant?
The rs1057519783 variant is extremely rare in the general population and is primarily identified as an acquired somatic mutation in patients with ALK-positive non-small cell lung cancer.
Frequently asked questions
Is the ALK G1202R mutation inherited from parents?
No, the ALK G1202R mutation is a somatic mutation, meaning it is acquired within the tumor cells during the development of cancer. It is not passed down from parents to children.
Does having this mutation mean my cancer is untreatable?
No, identifying this mutation does not mean the cancer is untreatable. It provides important information that helps oncologists select different targeted therapies that may be more effective against this specific resistance mechanism.
How is this mutation detected?
This mutation is typically detected through molecular testing of tumor tissue or circulating tumor DNA found in a blood sample, often using next-generation sequencing technology.
Can I prevent the development of the G1202R mutation?
There are no known lifestyle or dietary changes that can prevent the development of this specific mutation. It is a biological consequence of the cancer cells evolving under the pressure of targeted therapy.
Sources & further reading
Educational information only, last refreshed 9/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1057519783?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29